CERT
NVDA
SILO
Nvidia found another growth lane
Nvidia is doing what Nvidia does best: planting its flag in yet another corner of the AI map. This time, the company is expanding its life sciences presence through two separate initiatives with Certara and Silo Pharma.
Certara gets a BioNeMo boost
Certara said it is integrating Nvidia’s BioNeMo Agent Toolkit into its AI-driven drug development platform. Translation: Certara is trying to make its software smarter, faster, and a lot more agentic — the buzzword du jour for AI systems that can actually take action instead of just chatting about it.
The pitch is that these AI agents can help with everything from dosing strategies and clinical trial simulation to regulatory evidence prep. In other words, it’s trying to shave time off the painfully slow drug-development treadmill.
Silo Pharma wants in on the same game
On the other side of the deal parade, Silo Pharma’s subsidiary QwikAgents joined the Nvidia Developer Program. That gives it access to Nvidia’s software ecosystem, training, and optimization tools — basically, a backstage pass to the AI hardware/software universe.
Silo says that should help it beef up its autonomous AI agents for enterprise customers. Investors don’t need to memorize every product name here; the bigger takeaway is that Nvidia keeps turning its platform into the toll road everyone else wants to drive on.
Why investors should care
This isn’t a blockbuster acquisition or a giant revenue guide-up. But it does reinforce the same theme that keeps showing up in Nvidia’s story: the company isn’t just selling chips, it’s building the plumbing for the AI economy.
- Certara gets a more powerful AI drug-development stack
- Silo Pharma gets access to Nvidia’s developer ecosystem
- Nvidia keeps expanding into a high-value vertical where AI adoption could get sticky
Big picture: when everyone else is trying to build an AI feature, Nvidia is busy becoming the platform underneath it.